Cyclopharm Ltd
Company Profile
Business description
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
Contact
1 The Crescent
Unit 4
Kingsgrove
SydneyNSW2208
AUST: +61 295410411
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
109
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
stocks
ASX energy share undervalued ahead of earnings
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,311.90 | 125.80 | 1.37% |
| CAC 40 | 8,619.54 | 5.72 | 0.07% |
| DAX 40 | 26,137.60 | 136.29 | 0.52% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,890.57 | 32.87 | 0.30% |
| HKSE | 25,852.92 | 156.48 | -0.60% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,957.53 | 202.63 | 0.32% |
| NZX 50 Index | 13,903.46 | 128.53 | 0.93% |
| S&P 500 | 7,600.50 | 110.78 | 1.48% |
| S&P/ASX 200 | 9,145.80 | 122.80 | 1.36% |
| SSE Composite Index | 3,822.28 | 12.62 | 0.33% |